Neuren Pharmaceuticals shares lift as Daybue sales hit $139m in Q1
Make us a preferred source
Make us a preferred source on Google
The news: Shares in Neuren Pharmaceuticals rose in afternoon trade after the company reported strong first-quarter net sales for its Rett syndrome treatment Daybue.
Shares have risen 5.52% to $13 at 2:21pm AEST.
The numbers: Daybue net sales rose 20%, to USD101 million ($139 million), resulting in royalty income of USD10.4 million for Neuren, up from 23% in the previous corresponding period.
Neuren’s partner Acadia has reaffirmed its FY26 net sales guidance for Daybue of between USD460 million and USD490 million. Neuren expects full-year royalty income to range between USD50 million and USD54 million.
The context: Neuren stated that Daybue Stix recorded over 250 prescriptions. Approximately 30% of these were for new patients or those who had previously discontinued treatment.
The company added that Stix received a positive initial reception in the US, with caregiver satisfaction exceeding 80% and strong healthcare professional endorsement.
What they said: “I am very encouraged by the initial uptake and enthusiasm for Daybue Stix following the limited launch in the Centres of Excellence (COEs) and I look forward to seeing the impact of the recent broader US launch,” Neuren CEO Jon Pilcher said.
“I see significant potential upside remaining in the US, with penetration rates currently around 60% in the COEs and approximately 28% in the broader community,” he added.
The source: ASX
